Quotient Sciences Quotient Sciences

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Lineage Cell Therapeutics","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lineage Cell Therapeutics and Cancer Research UK Announce Encouraging Preliminary Phase 1 Study Results With VAC2 for the Treatment of Non-small Cell Lung Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Oracle Cancer Trust","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Researchers Target Thyroid Cancer with Triple Threat Drug Combination","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Ellipses Pharma","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Resistance-Busting ICR Drug Enters Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"New Molecular Entity","date":"March 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"New Type of Treatment Could Reawaken Immune Response Against Prostate Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Trial shows Benefits of Targeted Drug Against Early-Stage Breast Cancer with Inherited BRCA Mutation","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Drug Combination Shows Promise in Treatment-Resistant Advanced Ovarian Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"Apollo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Apollo Therapeutics and The Institute of Cancer Research Enter Into Collaboration For Cancer Drug Development","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery","country":"UNITED KINGDOM","productType":"Large molecule","productStatus":"Undisclosed","date":"November 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery"},{"orgOrder":0,"company":"The Institute of Cancer Research","sponsor":"NeoPhore","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"NeoPhore Signs Research Collaboration with The Institute of Cancer Research, London","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"}]

    Find Clinical Drug Pipeline Developments & Deals by The Institute of Cancer Research

    Menu

    The Institute of Cancer Research

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              The Institute of Cancer Research

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              NeoPhore Signs Research Collaboration with The Institute of Cancer Research, London

              Details:

              The collaboration will use NeoPhore's proprietary small molecule inhibitors of DNA mismatch repair to investigate single agent activity against tumours with defined genetic backgrounds.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Preclinical Product Type: Small molecule

              Recipient: NeoPhore

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration April 18, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              The Institute of Cancer Research

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Apollo Therapeutics and The Institute of Cancer Research Enter Into Collaboration For Cancer Drug Development

              Details:

              The collaboration combines the strengths and resources of both organisations to bring forward the development of novel therapies for cancer patients worldwide.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Product Type: Large molecule

              Recipient: Apollo Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration November 14, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              The Institute of Cancer Research

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Drug Combination Shows Promise in Treatment-Resistant Advanced Ovarian Cancer

              Details:

              The treatment combination comprised VS-6766 and defactinib, which can potentially hinder signals ovarian cancer to grow. VS-6766 is a dual RAF/MEK inhibitor of Verastem Oncology while defactinib is a FAK inhibitor.

              Lead Product(s): VS-6766,Defactinib

              Therapeutic Area: Oncology Product Name: VS-6766

              Highest Development Status: Phase II Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 19, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              The Institute of Cancer Research

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Trial shows Benefits of Targeted Drug Against Early-Stage Breast Cancer with Inherited BRCA Mutation

              Details:

              The OlympiA trial showed that adding olaparib for one year following standard treatment for patients who had an inherited BRCA mutation and early-stage, HER-2 negative breast cancer, cut the risk of their breast cancer returning by 42 per cent at a median 2.5-year follow-up.

              Lead Product(s): Olaparib

              Therapeutic Area: Oncology Product Name: Lynparza

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 04, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              The Institute of Cancer Research

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              New Type of Treatment Could Reawaken Immune Response Against Prostate Cancer

              Details:

              Study suggests that therapies which target CD38-such as the multiple myeloma drug daratumumab-could hold promise against prostate cancer too, by reawakening the anti-cancer immune response.

              Lead Product(s): Daratumumab

              Therapeutic Area: Oncology Product Name: Darzalex

              Highest Development Status: Undisclosed Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 07, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              The Institute of Cancer Research

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Resistance-Busting ICR Drug Enters Clinical Trial

              Details:

              Ellipses Pharma has rapidly progressed the development of EP0042 following successful negotiations between the ICR and the company, which were led by our Business and Innovation Office.

              Lead Product(s): EP0042

              Therapeutic Area: Oncology Product Name: EP0042

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Partner/Sponsor/Collaborator: Ellipses Pharma

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 19, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              The Institute of Cancer Research

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Researchers Target Thyroid Cancer with Triple Threat Drug Combination

              Details:

              The BRAF drug, called PLX4720, which targets this genetic mutation, was developed at the ICR, and produces significant results in both thyroid cancers and melanomas which carry the mutation.

              Lead Product(s): PLX4720,Talimogene laherparepvec,Antibodies

              Therapeutic Area: Oncology Product Name: PLX4720

              Highest Development Status: Preclinical Product Type: Small molecule

              Partner/Sponsor/Collaborator: Oracle Cancer Trust

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 09, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              The Institute of Cancer Research

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag United Kingdom
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Lineage Cell Therapeutics and Cancer Research UK Announce Encouraging Preliminary Phase 1 Study Results With VAC2 for the Treatment of Non-small Cell Lung Cancer

              Details:

              VAC2 demonstrated remarkably potent induction of immune responses in all patients dosed to date, with high levels of peripheral antigen-specific immunogenicity observed at multiple time points and confirmed by multimer staining.

              Lead Product(s): VAC2

              Therapeutic Area: Oncology Product Name: AST-VAC2

              Highest Development Status: Phase I Product Type: Vaccine

              Recipient: Lineage Cell Therapeutics

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 13, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
              Aspen API. More than just an API.
              Post Enquiry
              POST ENQUIRY